Naver's First-Quarter Profit Soars, Beating Consensus
By Kwanwoo Jun
Naver's first-quarter net profit jumped nearly 13-fold from a year earlier on solid growth in e-commerce and other core businesses, beating street views.
Net profit for the quarter ended in March was 555.80 billion Korean won ($406.3 million) compared with net profit of KRW43.70 billion in the same quarter a year earlier, the South Korean internet platform company said Friday.
That beat a FactSet-compiled consensus forecast of a KRW291.01 billion net profit.
Revenue during the quarter rose 11% on year to KRW2.526 trillion, while operating profit gained 33% on year to KRW439.30 billion.
The upbeat earnings come as the company is facing intensified competition from foreign e-commerce rivals, including Chinese platforms such as AliExpress and Temu expanding rapidly in South Korea.
Revenue grew across all major businesses, Naver said, led by its flagship e-commerce and search-platform businesses.
Revenue from e-commerce grew 16% from a year earlier in the first quarter and sales from search-platform advertising rose 6.2% on year during the quarter, according to the company.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
May 02, 2024 20:13 ET (00:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks